ReviewFrontiers in medicine2026
Hot flashes: a review.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hot flashes are the most common vasomotor symptom of menopause, affecting over 75% of women and significantly impairing quality of life. These symptoms are a frequent reason women seek medical care, often from primary care physicians. This review summarizes the clinical presentation, underlying pathophysiology, and current management of hot flashes. Clinically, symptoms include episodic heat sensation, flushing, and sweating, often associated with sleep disturbance. Pathophysiology involves estrogen withdrawal and thermoregulatory dysfunction, including a narrowed thermoneutral zone and increased neurokinin B signaling. Management includes lifestyle modifications and complementary therapies with variable evidence. Hormone replacement therapy remains the most effective treatment for appropriate candidates, while nonhormonal pharmacologic and non-pharmacologic approaches are commonly used when estrogen is contraindicated. Emerging targeted therapies offer additional treatment options. Treatment should be individualized based on symptom severity, patient preferences, and risk profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.